Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:15 2024-07-16 EDT			5-day change	1st Jan Change
8.65 ^EUR	-2.48%		-7.83%	-59.35%

07-11	Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk	DP
07-11	EVOTEC : Deutsche Bank is less optimistic	ZD

NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

January 31, 2023 at 10:49 am

EQS Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement
Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

31.01.2023 / 16:47 CET/CEST
Total Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of total number of voting rights

1. Details of issuer

Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany

2. Type of capital measure

	Type of capital measure	Date of status / date of effect
X	Conditional capital increase (Sec. 41 para. 2 WpHG)	31.01.2023
	Other capital measure (Sec. 41 para. 1 WpHG)

3. New total number of voting rights:

177185736

31.01.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Evotec SE
	Manfred Eigen Campus / Essener Bogen 7
	22419 Hamburg
	Germany
Internet:	www.evotec.com


End of News	EQS News Service

1548099 31.01.2023 CET/CEST

Latest news about Evotec SE

Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk	07-11	DP
EVOTEC : Deutsche Bank is less optimistic	07-11	ZD
Pfizer: collaboration agreement with Evotec in France	07-10	CF
Sector Update: Health Care Stocks Steady Premarket Wednesday	07-10	MT
Evotec, Pfizer Enter Research Collaboration on Metabolic, Infectious Diseases	07-10	MT
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, infectious Diseases	07-10	MT
Evotec with new recovery attempt - cooperation with Pfizer	07-10	DP
Evotec and Pfizer Collaborate to Advance Drug Discovery in France	07-10	CI
EVOTEC : Deutsche Bank reiterates its Buy rating	07-09	ZD
EVOTEC : Buy rating from RBC	07-08	ZD
Sandoz collaboration extension helps Evotec back to May high	07-08	DP
Evotec's Biologics Segment Expands Sandoz Partnership	07-08	MT
EVOTEC : RBC reiterates its Buy rating	07-03	ZD
Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board	06-30	CI
German Stocks Rise for Second Session	06-28	DJ
German Stocks Reverse Two-Session Losing Streak	06-27	DJ
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday	06-25	MT
Evotec Gets $39 Million Contract With U.S. Defense Department	06-25	DJ
Evotec Unit Bags Contract to Develop Accelerated Antibody Manufacturing Platform for US Government	06-25	MT
Evotec Subsidiary Gets Multi-Year US Defense Department Contract for Up to $39 Million	06-25	MT
Evotec receives additional contract from US Department of Defense	06-25	DP
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Evotec In Talks With Advisers Amid Takeover Worries	06-20	MT
European shares advance on tech, real estate boost; Swiss stocks shine	06-20	RE
Takeover fantasy drives Evotec recovery	06-20	DP

Chart Evotec SE

Duration

Period

More charts

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.65 EUR

Average target price

20.72 EUR

Spread / Average Target

+139.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-59.35%	1.72B
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research